Kunming Pharmaceutical Group Overview
- Year Founded
-
1951
- Status
-
Public
- Employees
-
5,275
- Stock Symbol
-
600422
- Investments
-
10
- Share Price
-
$2.22
- (As of Wednesday Closing)
Kunming Pharmaceutical Group General Information
Description
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
Contact Information
Website
www.kpc.com.cnCorporate Office
- No. 166 Keyi Road
- State New and High Technology Development Zone
- Kunming, Yunnan 650106
- China
Corporate Office
- No. 166 Keyi Road
- State New and High Technology Development Zone
- Kunming, Yunnan 650106
- China
Kunming Pharmaceutical Group Stock Performance
As of 14-May-2025, Kunming Pharmaceutical Group’s stock price is $2.22. Its current market cap is $1.68B with 757M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.22 | $2.23 | $1.68 - $3.32 | $1.68B | 757M | 14M | $0.11 |
Kunming Pharmaceutical Group Financials Summary
As of 31-Mar-2025, Kunming Pharmaceutical Group has a trailing 12-month revenue of $1.12B.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,738,186 | 1,498,272 | 2,139,723 | 1,502,145 |
| Revenue | 1,121,826 | 1,170,858 | 1,191,565 | 1,229,789 |
| EBITDA | 128,170 | 159,448 | 141,760 | 107,023 |
| Net Income | 84,289 | 90,319 | 76,427 | 56,898 |
| Total Assets | 1,749,019 | 1,727,561 | 1,734,529 | 1,367,089 |
| Total Debt | 230,811 | 114,117 | 127,076 | 165,177 |
Kunming Pharmaceutical Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kunming Pharmaceutical Group Patents
Kunming Pharmaceutical Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2016503077-A | Cyclodextrin carrier-based arteannuin compound complex and preparation method thereof | Pending | 14-Dec-2012 | ||
| JP-2016503078-A | Arteannuin-cyclodextrin conjugate and method for producing the same | Active | 14-Dec-2012 | ||
| JP-2016500116-A | Use of artemether in the preparation of a drug to treat leukemia | Pending | 29-Nov-2012 | ||
| EP-2292241-A1 | A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof | Inactive | 22-May-2008 | ||
| EP-2292241-A4 | A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof | Inactive | 22-May-2008 | A61K31/7048 |
Kunming Pharmaceutical Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kunming Pharmaceutical Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Kunming Pharmaceutical Group Investments & Acquisitions (10)
Kunming Pharmaceutical Group’s most recent deal was a Merger/Acquisition with Shenghuo Pharmaceutical Group for . The deal was made on 07-Jun-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Shenghuo Pharmaceutical Group | 07-Jun-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Leads Biolabs | 29-Oct-2020 | Later Stage VC | Drug Discovery | ||
| Shenogen | 29-Jul-2016 | Later Stage VC | Drug Discovery | ||
| Rani Therapeutics | 08-Mar-2016 | Later Stage VC | Drug Delivery | ||
| ChengYiSheng | 27-Jan-2016 | Early Stage VC | Application Software |
Kunming Pharmaceutical Group ESG
Risk Overview
Risk Rating
Updated December, 01, 2023
33.29 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
Kunming Pharmaceutical Group Exits (4)
Kunming Pharmaceutical Group’s most recent exit was on 08-Mar-2016 from Rani Therapeutics. The exit was categorized as with 12 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Rani Therapeutics | 08-Mar-2016 | Completed |
|
||
| ChengYiSheng | 27-Jan-2016 | Completed |
|
||
| Rani Therapeutics | 16-Jul-2015 | Completed |
|
||
| INNOGEN Pharm | 05-Dec-2014 | Joint Venture | Completed |
Kunming Pharmaceutical Group Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Hunan Djwk Medical | Changsha, China | 2004 |
Kunming Pharmaceutical Group FAQs
-
When was Kunming Pharmaceutical Group founded?
Kunming Pharmaceutical Group was founded in 1951.
-
Where is Kunming Pharmaceutical Group headquartered?
Kunming Pharmaceutical Group is headquartered in Kunming, China.
-
What is the size of Kunming Pharmaceutical Group?
Kunming Pharmaceutical Group has 5,275 total employees.
-
What industry is Kunming Pharmaceutical Group in?
Kunming Pharmaceutical Group’s primary industry is Pharmaceuticals.
-
Is Kunming Pharmaceutical Group a private or public company?
Kunming Pharmaceutical Group is a Public company.
-
What is Kunming Pharmaceutical Group’s stock symbol?
The ticker symbol for Kunming Pharmaceutical Group is 600422.
-
What is the current stock price of Kunming Pharmaceutical Group?
As of 14-May-2025 the stock price of Kunming Pharmaceutical Group is $2.22.
-
What is the current market cap of Kunming Pharmaceutical Group?
The current market capitalization of Kunming Pharmaceutical Group is $1.68B.
-
What is Kunming Pharmaceutical Group’s current revenue?
The trailing twelve month revenue for Kunming Pharmaceutical Group is $1.12B.
-
What is Kunming Pharmaceutical Group’s annual earnings per share (EPS)?
Kunming Pharmaceutical Group’s EPS for 12 months was $0.11.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
